TY - JOUR
T1 - Inclusion body myositis
T2 - The interplay between ageing, muscle degeneration and autoimmunity
AU - McLeish, E.
AU - Slater, N.
AU - Sooda, A.
AU - Wilson, A.
AU - Coudert, J. D.
AU - Lloyd, T. E.
AU - Needham, M.
N1 - Funding Information:
EM is a recipient of an Australian Government Research Training Program Scholarship at Murdoch University, Perth, WA, Australia. NS is a recipient of an Australian Government Research Training Program Scholarship at Murdoch University, Perth, WA, Australia. NS is also the recipient of a Perron Institute for Neurological and Translational Science Byron-Kakulas Prestige Scholarship. TEL is the recipient of a grant from the Peter and Carmen Lucia Buck Foundation.
Publisher Copyright:
© 2022 The Authors
PY - 2022/6
Y1 - 2022/6
N2 - Inclusion body myositis (IBM) is a slowly progressive muscle disease affecting ageing individuals. IBM presents with a distinctive pattern of weakness involving the quadriceps and finger flexor muscles, although other muscles including pharyngeal muscles become affected over time. Pathological hallmarks of IBM include autoimmune features, including endomysial infiltration by highly differentiated T cells, as well as degenerative features marked by intramyofibre protein aggregates organised into inclusion bodies. Despite some progress in understanding the cellular pathways involved in IBM, it remains untreatable, and the progression of the disease leads to progressive weakness, disability, wheelchair dependency and loss of independence. Therefore, there is an urgent need to improve our understanding of the underlying mechanisms and pathways involved in this disease to identify new treatment targets. Here, we discuss the current understanding of aetiopathogenesis, the interrelationship between autoimmunity and degeneration, and how ageing is a major influencer of both these features.
AB - Inclusion body myositis (IBM) is a slowly progressive muscle disease affecting ageing individuals. IBM presents with a distinctive pattern of weakness involving the quadriceps and finger flexor muscles, although other muscles including pharyngeal muscles become affected over time. Pathological hallmarks of IBM include autoimmune features, including endomysial infiltration by highly differentiated T cells, as well as degenerative features marked by intramyofibre protein aggregates organised into inclusion bodies. Despite some progress in understanding the cellular pathways involved in IBM, it remains untreatable, and the progression of the disease leads to progressive weakness, disability, wheelchair dependency and loss of independence. Therefore, there is an urgent need to improve our understanding of the underlying mechanisms and pathways involved in this disease to identify new treatment targets. Here, we discuss the current understanding of aetiopathogenesis, the interrelationship between autoimmunity and degeneration, and how ageing is a major influencer of both these features.
KW - Ageing
KW - Autoimmunity
KW - Inclusion body myositis
KW - Myodegeneration
KW - Pathogenesis
UR - http://www.scopus.com/inward/record.url?scp=85133353919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133353919&partnerID=8YFLogxK
U2 - 10.1016/j.berh.2022.101761
DO - 10.1016/j.berh.2022.101761
M3 - Review article
C2 - 35760741
AN - SCOPUS:85133353919
SN - 1521-6942
JO - Best Practice and Research in Clinical Rheumatology
JF - Best Practice and Research in Clinical Rheumatology
M1 - 101761
ER -